Blueprint Medicines CORP

Blueprint Medicines Corporation has completed its acquisition by Sanofi, with shares purchased for $129.00 cash plus a contingent value right per share, leading to delisting from Nasdaq.

Blueprint Medicines Corporation announced the successful outcomes of its Annual Meeting of Stockholders held on June 18, 2025, where shareholders elected Class I directors, approved executive compensation, and ratified Ernst & Young LLP as their independent auditor.

Sanofi has announced a definitive agreement to acquire Blueprint Medicines Corporation for an upfront cash payment of $9.1 billion, plus potential contingent value rights, significantly bolstering its rare immunological disease and early-stage immunology pipeline.

Blueprint Medicines announces positive Q1 2025 financial results, highlighted by a 61% year-over-year increase in AYVAKIT net product revenues, and raises its full-year revenue guidance for AYVAKIT.

Blueprint Medicines announces positive financial results for 2024, driven by AYVAKIT sales, and provides an optimistic outlook for 2025 with significant revenue growth expected.

Blueprint Medicines provided a business and strategic update, emphasizing growth in AYVAKIT revenue, expansion of their systemic mastocytosis franchise, and the development of BLU-808 for allergic and inflammatory diseases.

Blueprint Medicines announces its Q1 2025 financial results, highlighting increased product revenue driven by AYVAKIT/AYVAKYT sales and a net income of $0.5 million.

Blueprint Medicines reports third quarter 2024 financial results, showcasing revenue growth and advancements in its clinical pipeline.

Blueprint Medicines reports a net income of $39.1 million for the first half of 2024, driven by a debt extinguishment gain and strong product revenue growth, while also highlighting strategic portfolio adjustments.

Blueprint Medicines reports a strong first quarter of 2024, marked by significant product revenue growth and a substantial gain from debt extinguishment.

Blueprint Medicines' FY2024 10-K filing details the company's financial performance, strategic focus on allergy/inflammation and oncology/hematology, and pipeline advancements.

Blueprint Medicines Corporation released its annual financial report, detailing advancements in its oncology and mast cell-mediated disease treatment pipeline, including progress with AYVAKIT/AYVAKYT and other investigational therapies.

Blueprint Medicines Corporation's Chief Financial Officer, Michael Landsittel, converted all his common stock, restricted stock units, performance stock units, and stock options into cash and contingent value rights following the company's acquisition by Sanofi.

Blueprint Medicines Corporation Director Habib J. Dable disposed of all common stock and stock options on July 17, 2025, as part of the company's merger with Sanofi, receiving $129.00 per share plus a contingent value right.

Ariel Hurley, Principal Accounting Officer of Blueprint Medicines Corp, reported the disposition of common stock and stock options, and acquisition of shares from performance units, all in connection with the company's merger with Sanofi, effective July 17, 2025.

Blueprint Medicines Director John Tsai reported the conversion of his common stock, restricted stock units, and stock options into cash and contingent value rights as part of Sanofi's acquisition of the company, effective July 17, 2025.

A Blueprint Medicines Corporation director's equity holdings, including common stock, restricted stock units, and stock options, were converted into cash and contingent value rights as part of Sanofi's acquisition of the company.

Blueprint Medicines' Chief Medical Officer, Hewes L. Becker, reported the conversion of all his equity holdings, including common stock, PSUs, RSUs, and stock options, into cash and contingent value rights following the acquisition by Sanofi on July 17, 2025.

Blueprint Medicines Corporation has scheduled its 2025 Annual Meeting for June 18, 2025, and is providing proxy materials to stockholders for voting on key proposals.

Blueprint Medicines reports significant progress in 2024, driven by AYVAKIT sales and pipeline advancements, setting sights on \$2 billion in revenue by 2030.

Blueprint Medicines highlights a successful 2023 with regulatory approvals and commercial launches of AYVAKIT/AYVAKYT, setting the stage for continued growth and pipeline advancement in 2024.

Pentwater Capital Management LP and Matthew Halbower have disclosed a 6.0% beneficial ownership stake in Blueprint Medicines Corp., totaling 3.9 million shares.

T. Rowe Price Associates, Inc. has filed an Amendment No. 9 to Schedule 13G, reporting a 2.3% beneficial ownership in Blueprint Medicines Corp.

Avoro Capital Advisors and Behzad Aghazadeh have reported a beneficial ownership of 0.6% of Blueprint Medicines Corp's common stock.

Davidson Kempner Capital Management and its affiliates, including Anthony A. Yoseloff, have filed a Schedule 13G indicating they hold no beneficial ownership in Blueprint Medicines Corp as of July 14, 2025.

Avoro Capital Advisors LLC and Behzad Aghazadeh have disclosed a 6.0% beneficial ownership stake in Blueprint Medicines Corp, holding 3,850,000 shares of common stock for investment purposes.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a 4.8% beneficial ownership stake in Blueprint Medicines Corporation as of March 31, 2025.